GSK (GSK) Debt to Equity (2006 - 2026)
GSK (GSK) debt to equity from Mar 31, 2006 to Mar 31, 2026. The current GSK (GSK) debt to equity is 106.74%. You can export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Debt to Equity
Debt to Equity
Annual Debt to Equity change of GSK (GSK)
| Year | Debt to Equity | Change |
|---|---|---|
| 2025 | 108.20% | -12.92% |
| 2024 | 124.25% | -7.96% |
| 2023 | 135.00% | -31.83% |
| 2022 | 198.03% | +23.33% |
| 2021 | 160.56% | -13.73% |
| 2020 | 186.12% | -30.42% |
| 2019 | 267.50% | -61.20% |
| 2018 | 689.34% | +40.74% |
| 2017 | 489.80% | +29.37% |
| 2016 | 378.60% | +102.09% |
| 2015 | 187.34% | -50.77% |
| 2014 | 380.55% | +45.94% |
| 2013 | 260.75% | -17.22% |
| 2012 | 315.01% | +69.80% |
| 2011 | 185.52% | +9.19% |
| 2010 | 169.91% | +4.57% |
| 2009 | 162.49% | -20.39% |
| 2008 | 204.10% | +85.41% |
| 2007 | 110.08% | +88.20% |
| 2006 | 58.49% | N/A |
Comparison GSK (GSK) debt to equity with competitors
GSK (GSK) debt to equity is 106.74%.
| Ticker | Name | Debt to Equity | Upside |
|---|---|---|---|
| SNY | Sanofi | 27.50% | -74.24% |
| BIIB | Biogen Inc | 33.72% | -68.41% |
| JNJ | Johnson & Johnson | 67.73% | -36.55% |
| PFE | Pfizer Inc | 71.50% | -33.01% |
| AZN | Astrazeneca plc | 71.66% | -32.87% |
| NVO | Novo Nordisk | 72.09% | -32.47% |
| GILD | Gilead Sciences Inc | 94.30% | -11.66% |
| MRK | Merck & Co Inc | 107.06% | +0.30% |
| NVS | Novartis AG | 122.03% | +14.32% |
| LLY | Lilly(Eli) & Company | 139.02% | +30.23% |
| MDCX | MDCorp | 176.75% | +65.58% |
| MDCXW | Medicus Pharma Ltd warrant | 176.75% | +65.58% |
| GRFS | Grifols SA | 177.15% | +65.96% |
| BMY | Bristol-Myers Squibb Company | 219.95% | +106.06% |
| AMGN | AMGEN Inc | 623.75% | +484.34% |
| OGN | Organon & Company | 948.95% | +788.99% |